Lourdes
Calvo Martínez
Hospital Clinic Barcelona
Barcelona, EspañaPublicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (22)
2022
-
Clinical and Sociodemographic Determinants of Adherence to World Cancer Research Fund/American Institute for Cancer Research (WCRF/AICR) Recommendations in Breast Cancer Survivors—Health-EpiGEICAM Study
Cancers, Vol. 14, Núm. 19
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
2021
-
Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
The Lancet Oncology, Vol. 22, Núm. 6, pp. 858-871
-
Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trial
European Journal of Cancer, Vol. 148, pp. 382-394
2017
-
A PAM50-based chemoendocrine score for hormone receptor-positive breast cancer with an intermediate risk of relapse
Clinical Cancer Research, Vol. 23, Núm. 12, pp. 3035-3044
-
A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624
-
Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study
Clinical and Translational Oncology, Vol. 19, Núm. 1, pp. 91-104
-
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM “El Álamo III” retrospective study
PLoS ONE, Vol. 12, Núm. 10
-
Neoadjuvant therapy with weekly nanoparticle albumin-bound paclitaxel for luminal early breast cancer patients: Results from the nabrax study (GEICAM/2011-02), a multicenter, non-randomized, phase ii trial, with a companion biomarker analysis
Oncologist, Vol. 22, Núm. 11, pp. 1301-1308
-
Physical activity and breast cancer risk by pathological subtype
Gynecologic Oncology, Vol. 144, Núm. 3, pp. 577-585
2016
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
-
Standard versus continuous administration of capecitabine in metastatic breast cancer (GEICAM/2009-05): A randomized, noninferiority phase II trialwith a pharmacogenetic analysis
Oncologist, Vol. 20, Núm. 2, pp. 111-112
2013
2011
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
2009
2008
-
A single-nucleotide polymorphismin the aromatase gene is associated with the efficacy of the aromatase inhibitor letrozole in advanced breast carcinoma
Clinical Cancer Research, Vol. 14, Núm. 3, pp. 811-816